Skip to main content
S&P 5007,663.43-1.21%DOW52,867.98+0.02%NASDAQ26,008.86-2.60%BTC$81,395.00-3.35%ETH$2,391.93-3.37%GOLD$4,036.20-0.60%OIL$99.27-0.20%
Smart Investors Daily
SID Premium
SE

NASDAQ · SEER

Seer, Inc.

Healthcare · Biotechnology

$1.97

Down-$0.06 (-2.96%)

Updated Oct 23, 2026, 6:17 AM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
101.26M
P/E ratio
-1.29
Dividend yield
0.00%
52-week range
$1.55 – $2.41
Volume
106.02K
Avg. volume
127.71K

Price performance · SEER

SEER price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 22, 2026

SEER closed at $1.97 after 21 trading sessions, up 5.35% for the selected period.

Last close
$1.97
Period change
+5.35%
Period low
$1.87
Period high
$2.33
Daily close
View OHLC price history
SEER OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 22, 2026$2.03$2.035$1.955$1.97106.02K
Oct 21, 2026$1.97$2.0999$1.97$2.03121.99K
Oct 20, 2026$2.03$2.05$1.98$1.98553.74K
Oct 19, 2026$2.04$2.09$2.015$2.0243K
Oct 16, 2026$2.03$2.10$2.01$2.03147.37K
Oct 15, 2026$2.08$2.095$2.04$2.04173.29K
Oct 14, 2026$2.10$2.115$2.06$2.0883.88K
Oct 13, 2026$2.13$2.155$2.105$2.11107.9K
Oct 12, 2026$2.19$2.21$2.145$2.15103.68K
Oct 9, 2026$2.16$2.25$2.14$2.19204.2K
Oct 8, 2026$2.21$2.22$2.165$2.17265.94K
Oct 7, 2026$2.17$2.275$2.135$2.21265.35K
Oct 6, 2026$2.34$2.37$2.175$2.19144.33K
Oct 5, 2026$2.23$2.375$2.23$2.33595.87K
Oct 2, 2026$2.25$2.265$2.215$2.25200.54K
Oct 1, 2026$2.15$2.23$2.1001$2.20311.95K
Sep 30, 2026$2.15$2.27$2.1421$2.23752.98K
Sep 29, 2026$2.03$2.16$2.0005$2.15583.35K
Sep 28, 2026$1.90$2.06$1.90$2.03699.07K
Sep 25, 2026$1.88$1.955$1.865$1.91244.11K
Sep 24, 2026$1.80$1.90$1.78$1.87767.63K

Latest SEER news

The latest Smart Investors Daily articles mentioning SEER.

Stock researchCompany · Overview

SEER research

Overview

Company profile and research snapshot.

Company profile

Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.06
Implied upside
—
Analysts
7
SEER recent ratings
DateFirmRatingTarget
May 4, 2026Canaccord GenuityBuy—
Aug 13, 2024Morgan StanleyEqual-Weight—
Mar 5, 2024Morgan StanleyEqual-Weight—
Feb 21, 2023Morgan StanleyEqual-Weight—
Jan 4, 2023B of A SecuritiesUnderperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Seer to Report Third Quarter 2026 Financial Results on November 10, 2026

REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2026 on Tuesday, November 10, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archi

Yahoo · Sep 23, 2026

Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026

John Chambers, PhD, and Nilanjana Sadhu, PhD, to share early insights from pioneering population-scale proteomic study of 10,000 participants in SingaporeREDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Conventi

Yahoo · Sep 21, 2026

Seer Announces CFO Transition

REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Company’s President, Chief Financial Officer and Treasurer, will depart Seer effective October 1, 2026, to pursue a new opportunity at a private company. Charles Endweiss, who has been Seer’s Vice President, Financial Planning & Analysis, will serve as Treasurer, principal financia

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By